PMID- 20853178
OWN - NLM
STAT- MEDLINE
DCOM- 20110111
LR  - 20211203
IS  - 1776-260X (Electronic)
IS  - 1776-2596 (Linking)
VI  - 5
IP  - 3
DP  - 2010 Sep
TI  - Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic 
      targets in malignant glioma: current clinical status and perspectives.
PG  - 183-91
LID - 10.1007/s11523-010-0154-5 [doi]
AB  - Despite advances in the understanding of the molecular biology of glioblastomas 
      (GB), these neoplasms still are incurable with conventional therapies. Current 
      efforts therefore focus on the development of new molecular approaches that 
      exploit the genetic aberrations of cancer cells. Based on their frequent 
      activation or mutation in human GB and their paramount role for the maintenance 
      of the neoplastic phenotype, both the epidermal growth factor receptor (EGFR) and 
      the mammalian target of rapamycin (mTOR) are plausible targets for molecular 
      therapies. However, clinical trials with drugs targeting EGFR or mTOR, so far, 
      have produced largely disappointing results. In this article, we review 
      strategies targeting EGFR and mTOR as therapies for malignant glioma. Recent 
      advances in the understanding of the complex signaling network involved are 
      highlighted and the results of clinical trials are summarized. Mechanisms of 
      resistance are explored, and potential future directions as well as trends in 
      preclinical and clinical development are discussed.
FAU - Ronellenfitsch, Michael W
AU  - Ronellenfitsch MW
AD  - Dr. Senckenberg Institute of Neurooncology, Center of Neurology and Neurosurgery, 
      Goethe-University Hospital, Schleusenweg 2-16, 60528 Frankfurt am Main, Germany. 
      m.ronellenfitsch@med.uni-frankfurt.de
FAU - Steinbach, Joachim P
AU  - Steinbach JP
FAU - Wick, Wolfgang
AU  - Wick W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20100919
PL  - France
TA  - Target Oncol
JT  - Targeted oncology
JID - 101270595
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Brain Neoplasms/*drug therapy/metabolism
MH  - Clinical Trials as Topic
MH  - ErbB Receptors/*antagonists & inhibitors
MH  - Glioma/*drug therapy/metabolism
MH  - Humans
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
EDAT- 2010/09/21 06:00
MHDA- 2011/01/12 06:00
CRDT- 2010/09/21 06:00
PHST- 2010/05/25 00:00 [received]
PHST- 2010/08/04 00:00 [accepted]
PHST- 2010/09/21 06:00 [entrez]
PHST- 2010/09/21 06:00 [pubmed]
PHST- 2011/01/12 06:00 [medline]
AID - 10.1007/s11523-010-0154-5 [doi]
PST - ppublish
SO  - Target Oncol. 2010 Sep;5(3):183-91. doi: 10.1007/s11523-010-0154-5. Epub 2010 Sep 
      19.